(3-fluorophenyl)(4-fluorophenyl)methanol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-fluorophenyl)(4-fluorophenyl)methanol
• 英文别名: (3-fluorophenyl)-(4-fluorophenyl)methanol
• 化学式: C₁₃H₁₀F₂O
• mdl: MFCD06201345
• 分子量: 220.219
• InChiKey: SBCIQJIBLBKOAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3-fluorophenyl)(4-fluorophenyl)methanol 在 potassium carbonate 、 对甲苯磺酸 、 sodium iodide 作用下， 以 乙腈 、 苯 为溶剂， 反应 24.0h， 生成 ((3R,4S)-1-{3-[(4-Fluoro-phenyl)-(3-fluoro-phenyl)-methoxy]-propyl}-3-methyl-piperidin-4-yl)-acetic acid ethyl ester
  参考文献：
  名称：

  New N-(benzhydryloxyalkyl)-4-(carboxy/carbamoylmethyl) piperidine derivatives with antidepressant activity

  摘要：

  Several benzhydryloxylalkylpiperidine derivatives were prepared with the aim of obtaining new antidepressant compounds. The influence of the length of the aliphatic chain and of aromatic and piperidine ring substitutions was studied. The pharmacological activity of compounds was investigated in vivo by means of a screening comprising four pharmacological tests: antagonism of reserpine and apomorphine hypothermia; increase of yohimbine induced mortality; and antagonism of immobility in tail suspension test. An in-depth pharmacological study was performed with the more active compounds and a binding study to serotonin (5-HT), norepinephrine (NE) and dopamine (DA) reuptake sites was performed for the preferred compounds. The most active compounds [+], [-]-cis-31, 32 and 46 exhibited an interesting psychopharmacological profile after intraperitoneal administration. This profile was confirmed by the oral route for 31 and 46. In vitro, these compounds showed a non-selective inhibition of DA, NE and 5-HT uptake.

  DOI：

  10.1016/s0223-5234(97)83972-4

文献信息

• HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST
  申请人：Okada Makoto

  公开号：US20130085127A1

  公开（公告）日：2013-04-04

  A heterocyclic compound useful as an antiallergic agent is provided. A compound represented by the following formula (1) or a salt thereof: wherein the ring A is a homocyclic or heterocyclic ring; the ring B is a heterocyclic ring which contains G and nitrogen atom N as constituent atoms thereof, wherein G is CH or N; R 1 is a carbonyl group or an alkylene group; R 2a and R 2b are an alkyl group, a cycloalkyl group, an aryl group, or a heterocyclic group; X is an oxygen atom or a sulfur atom; Z is a hydroxyl group, an alkoxy group, a cycloalkyloxy group, an aryloxy group, an aralkyloxy group, an amino group, or an N-substituted amino group; and n is 0 or 1; with the proviso that when the ring A is a benzene ring or when the ring B is a piperazine ring, R 1 is an alkylene group which may have a substituent.

  提供一种作为抗过敏剂使用的杂环化合物。所述化合物由以下式（1）或其盐表示：其中环A是同环或杂环；环B是一个杂环，其中包含G和氮原子N作为其组成原子，其中G是CH或N；R1是一个羰基或一个烷基基团；R2a和R2b是烷基基团、环烷基基团、芳基团或杂环基团；X是一个氧原子或硫原子；Z是一个羟基、烷氧基、环烷氧基、芳氧基、芳基氧基、氨基或N-取代氨基；n为0或1；但条件是当环A为苯环或环B为哌嗪环时，R1是可能有取代基的烷基基团。
• QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF
  申请人：Amari Gabriele

  公开号：US20100035922A1

  公开（公告）日：2010-02-11

  Quinuclidine carbonate derivatives act as muscarinic receptor antagonists and are effective for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases.

  奎奴克啶碳酸盐衍生物作为毒蕈碱受体拮抗剂，对预防和/或治疗支气管阻塞或炎症性疾病有效。
• Quinuclidine carbonate salts and medicinal composition thereof
  申请人：Chiesi Farmaceutici S.p.A.

  公开号：US08039483B2

  公开（公告）日：2011-10-18

  Quinuclidine carbonate derivatives act as muscarinic receptor antagonists and are effective for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases.

  喹诺啡啶碳酸盐衍生物作为肌肉型乙酰胆碱受体拮抗剂，对于预防和/或治疗支气管阻塞性或炎症性疾病是有效的。
• Substituted naphthyridinone compounds useful as T cell activators
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10669272B2

  公开（公告）日：2020-06-02

  Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

  公开的是式 (I) 化合物： 或其盐，其中R1、R2、R3、R4、R5 和 m 在本文中定义。还公开了使用此类化合物抑制二酰甘油激酶α（DGKα）和二酰甘油激酶zeta（DGKζ）中的一种或两种的活性的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗病毒感染和增殖性疾病，如癌症。
• WO2020006018A5
  申请人：——

  公开号：WO2020006018A5

  公开（公告）日：2022-07-04